EQT emerges sole bidder for OmniActive Health Technologies

Swedish investment powerhouse EQT is now leading the charge as the exclusive bidder for OmniActive Health Technologies, following the rejection of a competing offer from Temasek and Novo Holdings. Known for its robust presence in the nutraceutical industry, OmniActive is under the umbrella of TA Associates and has a strong export footprint in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91pvszd
via IFTTT

Read More

MSD India ropes in Madhuri Dixit for cervical cancer awareness drive

US pharma major MSD has partnered with Bollywood actor Madhuri Dixit for a nationwide cervical cancer awareness program in India. The initiative aims to encourage conversations about women's preventive healthcare and prompt discussions with doctors regarding cervical cancer and its prevention. Digital films featuring Dixit have been released to amplify the campaign's reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EPz24lq
via IFTTT

Read More

Hantavirus outbreak on cruise ship: India monitors situation, no cases on Indian soil

The Union Health Ministry is monitoring hantavirus cases on the cruise ship MV Hondius, where three deaths and five confirmed infections have occurred. India has no domestic cases and its surveillance networks are active. The Andes strain, with limited human-to-human transmission, has been identified, and the WHO assesses the public health risk as low.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yKRBPXu
via IFTTT

Read More

India faces no immediate public health threat from hantavirus: NIV chief

Two Indian nationals aboard a cruise ship have reportedly contracted hantavirus. Indian health officials assure the public that these cases appear isolated. There is no immediate public health threat to India. Experts confirm hantavirus does not spread easily among people. India possesses adequate laboratory capacity for diagnosis. Standard rodent control and sanitation remain key preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkVsenY
via IFTTT

Read More

Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT

Read More

Dr Reddy's and Nestle Health Science strengthen presence in diabetes, obesity nutrition space

Dr Reddy's teams up with Nestle Health Science to introduce Celevida GLP+, a specialized supplement crafted for those navigating the challenges of GLP-1/GIP therapy for type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/shVKNgM
via IFTTT

Read More

Venus Remedies expands Latin America presence with Argentina nod for antibiotic

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin America expansion. Argentina is a key market for critical care therapies. Ceftriaxone is vital for treating serious bacterial infections. This authorization strengthens Venus Remedies' global presence and commitment to accessible anti-infective treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x1SmKLv
via IFTTT

Read More